LA JOLLA, Calif., July 30, 2019 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs, today announced the appointment of
Cris Calsada as its new Chief
Financial Officer effective August 30,
2019. Ms. Calsada joins Regulus from Sanifit where she has
served as Chief Financial Officer since December 2017. Ms.
Calsada brings to Regulus' senior management team a unique
combination of financial, operational and managerial experience.
She has over 20 years of leadership experience in the life sciences
and technology industries. Prior to her employment with
Sanifit, Ms. Calsada was self-employed as a finance consultant to
various life sciences companies. From 2004 until its
acquisition in 2015, she served in positions of increasing
responsibility with Ambrx, most recently serving as its Chief
Operating Officer and Vice President of Finance. Prior to Ambrx,
she worked for Sony Online Entertainment as its Executive Director
of Finance and Controller. Earlier in her career, she practiced as
a certified public accountant. Ms. Calsada received a B.S. in
Business Administration with emphasis in Accounting from
San Diego State University and an
M.B.A. from the University of Southern
California Marshall School of Business.
"We are excited to welcome Cris to the Regulus team," said Jay
Hagan CEO of Regulus. "Cris brings a strong track record of
execution to the Regulus senior management team and I look forward
to working with her as we advance our pipeline of microRNA
therapeutics."
"I am privileged and eager to join the Regulus leadership team
at such a pivotal time for the business," said Cris Calsada. "The landscape of RNA
related therapeutics is evolving at a rapid pace and with its
recent financing from a strong investor syndicate, I believe
Regulus is well positioned to advance its innovative pipeline."
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus maintains its
corporate headquarters in La
Jolla, CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the advancement of
Regulus' preclinical and clinical activities, including statements
regarding the timing of preclinical and clinical
activities. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and feedback from the
FDA. These and other risks are described in additional detail
in Regulus' filings with the Securities and Exchange
Commission. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-appoints-cris-calsada-as-chief-financial-officer-300892826.html
SOURCE Regulus Therapeutics Inc.